Developer docs
API playgroundTry for free, no card

Search company profiles

Seroba Life Sciences

Full company profile

uuid00024aj

Namestring
Seroba Life Sciences
Legal namestring
Seroba Life Sciences
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Seroba Life Sciences is a Dublin-headquartered European venture capital firm founded in 2009 that invests in early-stage biotech and medtech companies. The firm provides venture capital investment and operational support to portfolio companies developing innovative healthcare technologies, with stated focus on "value creation through backing winning innovations in biotech and medtech." Its portfolio spans gene therapy (Complement Therapeutics, Coave Therapeutics, Covagen), medical devices for stroke treatment and surgical intervention (Perfuze, Ryme Medical, Veryan-Med, Novate), dialysis technology (Quanta Dialysis Technologies), neurology (Sibylla, Shiratronics), and AI-enabled diagnostics (Deciphex).

Seroba's business model is that of a traditional venture capital partnership. Revenue is generated through fund management fees on committed capital and carried interest on portfolio exits; the firm does not disclose pricing or revenue publicly. The firm is backed by institutional limited partners including the European Investment Fund, CDP Venture Verticals, Enterprise Ireland, and the National Treasury Management Agency (NTMA), and maintains memberships in Invest Europe, the Irish Venture Capital Association, and the Principles for Responsible Investment. Distribution of capital is conducted through direct investment relationships with portfolio companies, primarily across Ireland and broader European markets.

The firm differentiates through complementary investment and operational industry expertise across an 11-person team of partners and specialists. Unlike a product company, Seroba does not develop proprietary technology; its value proposition rests on capital deployment, strategic guidance, industry connections, and operational support for portfolio companies addressing funding and scaling gaps in European life sciences innovation.

Short descriptiontext

Seroba Life Sciences is a Dublin-based European venture capital firm founded in 2009 that invests venture capital and provides operational support to early-stage biotech and medtech companies across Europe, backed by institutional LPs including the EIF, CDP Venture, Enterprise Ireland, and NTMA.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, life sciences investment, biotech venture capital, medtech investment, portfolio company funding
Industry1 code
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
NAICS code1 code
  • Miscellaneous Financial Investment Activities523999
SIC code1 code
  • Investment Advice6282
Product category
Life Sciences Venture Capital
Social media profiles1 record
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Seroba Life Sciences is a European life sciences venture capital firm that invests equity capital and provides operational support to early-stage biotech and medtech companies developing innovative science-based healthcare solutions. The firm generates returns through portfolio company exits, fund management fees, and carried interest, and is backed by institutional limited partners including the European Investment Fund, CDP Venture, Enterprise Ireland, and the NTMA.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Seroba is a European life sciences venture capital firm, not a product company. As a VC firm, it does not develop or offer its own technology products or services. Seroba backs portfolio companies in the biotech and medtech sectors including Shiratronics, Ryme Medical, Sibylla, Coave Therapeutics, Quanta Dialysis Technologies, Veryan-Med, Novate, and Covagen, among others. These portfolio companies develop their own distinct products in areas such as stroke treatment catheters, gene therapies, dialysis technologies, and medical devices. Seroba's role is investment and operational support rather than product development.

Product and service1 record
1European life sciences venture capital fund (general category)
CategoryVenture capital fund management
Description

Venture capital fund management services that deploy equity capital into early-stage European biotech and medtech companies and provide operational support, strategic guidance, and industry connections; the fund is backed by institutional limited partners including the European Investment Fund, CDP Venture Vertical, Enterprise Ireland, and the National Treasury Management Agency.

Partnership3 partners
Strategic tierCoreTypeOthers
Description

Seroba is a member of Invest Europe and has contributed to developing the organization's position paper on Biotech and Healthcare: The Venture Capital and Private Equity Perspective, working alongside BGV and Hadean to shape European venture capital policy and industry standards.

2Irish Venture Capital Association (IVCA)
Strategic tierCoreTypeOthers
Description

Seroba is a member of the Irish Venture Capital Association (IVCA), the leading body representing venture capital and private equity firms in Ireland.

serobavc.com
Strategic tierMinorTypeOthers
Description

Seroba is a signatory to the Principles for Responsible Investment (PRI), demonstrating commitment to responsible investment practices in the life sciences sector.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Forbion is a leading European life sciences venture capital firm investing in biotech and medtech. It is a direct peer to Seroba, competing for the same European biotech deal flow with a larger fund base and a similar thesis of building biotech companies around breakthrough science.

TypeDirect peer
Description

BGV is a Dutch-based European venture capital firm focused on early-stage biotech. BGV is a direct peer to Seroba — they co-led Invest Europe's biotech position paper together, operate at similar fund sizes, and target the same European biotech startup segment.

TypeDirect peer
Description

Sofinnova Partners is one of Europe's largest healthcare and life sciences VC firms, investing across biotech and medtech from early to late stage. It is a direct peer operating in the same European life sciences VC category as Seroba, though typically at larger fund sizes.

4Hadean Ventures
TypeDirect peer
Description

Hadean Ventures is a Nordic/European life sciences VC firm investing in biotech and medtech. It is a direct peer to Seroba — they co-developed the Invest Europe position paper together and share a similar European regional focus.

TypeDirect peer
Description

Gilde Healthcare is a Netherlands-based European healthcare VC firm investing across therapeutics, medtech, and digital health. It is a direct peer to Seroba, targeting similar European biotech/medtech founders with comparable ticket sizes.

TypeDirect peer
Description

LSP is a long-established European life sciences VC firm investing across all stages of biotech and medtech. It is a direct peer to Seroba in the European life sciences VC category, with deeper AUM and broader stage focus.

TypeDirect peer
Description

Andera Partners (formerly Edmond de Rothschild Investment Partners) operates a dedicated life sciences venture franchise in Europe. It is a direct peer to Seroba, competing for European biotech and medtech deals across similar stages.

TypeDirect peer
Description

Kurma Partners is a Paris-based European life sciences VC firm investing in biotech and digital health. It is a direct peer to Seroba, sharing the European focus and life sciences specialty, with overlapping geographies and target company profiles.

TypeBroad incumbent
Description

Corporate venture arms of large pharma (Lilly, Novartis, Roche) are broader incumbents in the European life sciences investment space. They participate in the same syndicates as Seroba at the growth stage but with much larger balance sheets and strategic commercial interests.

TypeOthers
Description

Enterprise Ireland is one of Seroba's key institutional LPs but also operates direct investment programs supporting Irish and European life sciences startups. It is an adjacent ecosystem player — both LP to and investor alongside Seroba in the same companies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment49 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Seroba Life Sciences

Life Sciences Venture Capitalseroba-lifesciences.com

Seroba Life Sciences is a Dublin-based European venture capital firm founded in 2009 that invests venture capital and provides operational support to early-stage biotech and medtech companies across Europe, backed by institutional LPs including the EIF, CDP Venture, Enterprise Ireland, and NTMA.

What Seroba Life Sciences does

Seroba Life Sciences is a Dublin-headquartered European venture capital firm founded in 2009 that invests in early-stage biotech and medtech companies. The firm provides venture capital investment and operational support to portfolio companies developing innovative healthcare technologies, with stated focus on "value creation through backing winning innovations in biotech and medtech." Its portfolio spans gene therapy (Complement Therapeutics, Coave Therapeutics, Covagen), medical devices for stroke treatment and surgical intervention (Perfuze, Ryme Medical, Veryan-Med, Novate), dialysis technology (Quanta Dialysis Technologies), neurology (Sibylla, Shiratronics), and AI-enabled diagnostics (Deciphex).

Seroba's business model is that of a traditional venture capital partnership. Revenue is generated through fund management fees on committed capital and carried interest on portfolio exits; the firm does not disclose pricing or revenue publicly. The firm is backed by institutional limited partners including the European Investment Fund, CDP Venture Verticals, Enterprise Ireland, and the National Treasury Management Agency (NTMA), and maintains memberships in Invest Europe, the Irish Venture Capital Association, and the Principles for Responsible Investment. Distribution of capital is conducted through direct investment relationships with portfolio companies, primarily across Ireland and broader European markets.

The firm differentiates through complementary investment and operational industry expertise across an 11-person team of partners and specialists. Unlike a product company, Seroba does not develop proprietary technology; its value proposition rests on capital deployment, strategic guidance, industry connections, and operational support for portfolio companies addressing funding and scaling gaps in European life sciences innovation.

Seroba Life Sciences firmographics

Firmographics
Name
Seroba Life Sciences
Legal name
Seroba Life Sciences
Website
https://seroba-lifesciences.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
Seroba Life Sciences is a Dublin-based European venture capital firm founded in 2009 that invests venture capital and provides operational support to early-stage biotech and medtech companies across Europe, backed by institutional LPs including the EIF, CDP Venture, Enterprise Ireland, and NTMA.
Ownership category
akta.pro rank

Seroba Life Sciences industry classification

Industry
Product category
Life Sciences Venture Capital
NAICS
Miscellaneous Financial Investment Activities (523999)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity

Keywords

  • Venture capital investing
  • Life sciences investment
  • Biotech venture capital
  • Medtech investment
  • Portfolio company funding

Where Seroba Life Sciences is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices1 record

Markets served

Seroba Life Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Distribution channels1 record

Marketing channels4 records

Seroba Life Sciences product offering

Product offering

Core offering

Seroba Life Sciences is a European life sciences venture capital firm that invests equity capital and provides operational support to early-stage biotech and medtech companies developing innovative science-based healthcare solutions. The firm generates returns through portfolio company exits, fund management fees, and carried interest, and is backed by institutional limited partners including the European Investment Fund, CDP Venture, Enterprise Ireland, and the NTMA.

Product overview

Seroba is a European life sciences venture capital firm, not a product company. As a VC firm, it does not develop or offer its own technology products or services. Seroba backs portfolio companies in the biotech and medtech sectors including Shiratronics, Ryme Medical, Sibylla, Coave Therapeutics, Quanta Dialysis Technologies, Veryan-Med, Novate, and Covagen, among others. These portfolio companies develop their own distinct products in areas such as stroke treatment catheters, gene therapies, dialysis technologies, and medical devices. Seroba's role is investment and operational support rather than product development.

Differentiator

Problem solved

Functional benefit

Products and services

  • European life sciences venture capital fund (general category) Venture capital fund management services that deploy equity capital into early-stage European biotech and medtech companies and provide operational support, strategic guidance, and industry connections; the fund is backed by institutional limited partners including the European Investment Fund, CDP Venture Vertical, Enterprise Ireland, and the National Treasury Management Agency.

Companies that use Seroba Life Sciences

Customer profile

Segments1 record

Ideal customer profiles2 records

Seroba Life Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Seroba Life Sciences partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Invest EuropecoreOthersSeroba is a member of Invest Europe and has contributed to developing the organization's position paper on Biotech and Healthcare: The Venture Capital and Private Equity Perspective, working alongside BGV and Hadean to shape European venture capital policy and industry standards.
  • Irish Venture Capital Association (IVCA)coreOthersSeroba is a member of the Irish Venture Capital Association (IVCA), the leading body representing venture capital and private equity firms in Ireland.
  • Principles for Responsible Investment (PRI)minorOthersSeroba is a signatory to the Principles for Responsible Investment (PRI), demonstrating commitment to responsible investment practices in the life sciences sector.

Recent moves5 records

Expansion highlights4 records

Seroba Life Sciences competitors and assessment

Company assessment

Direct peers

  • Forbion: Forbion is a leading European life sciences venture capital firm investing in biotech and medtech. It is a direct peer to Seroba, competing for the same European biotech deal flow with a larger fund base and a similar thesis of building biotech companies around breakthrough science.
  • BioGeneration Ventures (BGV): BGV is a Dutch-based European venture capital firm focused on early-stage biotech. BGV is a direct peer to Seroba — they co-led Invest Europe's biotech position paper together, operate at similar fund sizes, and target the same European biotech startup segment.
  • Sofinnova Partners: Sofinnova Partners is one of Europe's largest healthcare and life sciences VC firms, investing across biotech and medtech from early to late stage. It is a direct peer operating in the same European life sciences VC category as Seroba, though typically at larger fund sizes.
  • Hadean Ventures: Hadean Ventures is a Nordic/European life sciences VC firm investing in biotech and medtech. It is a direct peer to Seroba — they co-developed the Invest Europe position paper together and share a similar European regional focus.
  • Gilde Healthcare: Gilde Healthcare is a Netherlands-based European healthcare VC firm investing across therapeutics, medtech, and digital health. It is a direct peer to Seroba, targeting similar European biotech/medtech founders with comparable ticket sizes.
  • LSP (Life Sciences Partners): LSP is a long-established European life sciences VC firm investing across all stages of biotech and medtech. It is a direct peer to Seroba in the European life sciences VC category, with deeper AUM and broader stage focus.
  • Andera Partners: Andera Partners (formerly Edmond de Rothschild Investment Partners) operates a dedicated life sciences venture franchise in Europe. It is a direct peer to Seroba, competing for European biotech and medtech deals across similar stages.
  • Kurma Partners: Kurma Partners is a Paris-based European life sciences VC firm investing in biotech and digital health. It is a direct peer to Seroba, sharing the European focus and life sciences specialty, with overlapping geographies and target company profiles.

Broad incumbents

  • Eli Lilly European Venture Fund / Lilly Ventures-type corporate VCs: Corporate venture arms of large pharma (Lilly, Novartis, Roche) are broader incumbents in the European life sciences investment space. They participate in the same syndicates as Seroba at the growth stage but with much larger balance sheets and strategic commercial interests.

Others

  • Enterprise Ireland (Growth Capital / Seed Funds): Enterprise Ireland is one of Seroba's key institutional LPs but also operates direct investment programs supporting Irish and European life sciences startups. It is an adjacent ecosystem player — both LP to and investor alongside Seroba in the same companies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Seroba Life Sciences social profiles

Digital presence

Seroba Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Seroba Life Sciences leadership team

Management profile

Number of profiles

Profiles15 records

Seroba Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Seroba Life Sciences M&A and investment

M&A and investment

M&A

Investments49 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seroba Life Sciences

What does Seroba Life Sciences do?

Seroba Life Sciences is a European life sciences venture capital firm that invests equity capital and provides operational support to early-stage biotech and medtech companies developing innovative science-based healthcare solutions. The firm generates returns through portfolio company exits, fund management fees, and carried interest, and is backed by institutional limited partners including the European Investment Fund, CDP Venture, Enterprise Ireland, and the NTMA.

Is Seroba Life Sciences a public or private company?

Seroba Life Sciences is a private company. It is classified as private equity controlled and is currently operating.

When was Seroba Life Sciences founded?

Seroba Life Sciences was founded in 2002. It employs 11 to 50 people.

Where is Seroba Life Sciences based?

Seroba Life Sciences is headquartered in Dublin, Ireland, in the Europe region.

Who are Seroba Life Sciences's main competitors?

Direct peers on record are Forbion, BioGeneration Ventures (BGV), Sofinnova Partners, Hadean Ventures, Gilde Healthcare, LSP (Life Sciences Partners), Andera Partners and Kurma Partners. Eli Lilly European Venture Fund / Lilly Ventures-type corporate VCs is listed as a broad incumbent. Enterprise Ireland (Growth Capital / Seed Funds) is listed as an others.

Does Seroba Life Sciences have an API?

No public API is recorded for Seroba Life Sciences.

What industry is Seroba Life Sciences in?

Seroba Life Sciences's product category is Life Sciences Venture Capital. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 523999 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SerobavcSeroba Announces Its investment in Ryme Medical as Part of Series A Financing – Seroba LifesciencesSeroba, a European life sciences venture capital firm, has invested in Ryme Medical as part of its Series A financing round aimed at advancing innovative medical technologies. The funds will support Ryme Medical's efforts to reach clinical and regulatory milestones with its technology addressing Chronic Obstructive Pulmonary Disease (COPD), which affects over 320 million people worldwide. This investment reflects Seroba's commitment to improving healthcare solutions globally.Business Wire BlogSeroba and Kurma Partners Announce Complementary Series B Funding for Vico Therapeutics totaling €65.8 million ($70.7 million)Seroba and Kurma Partners completed the second closing of Vico Therapeutics' Series B, adding €11.5 million to an existing €54.3 million, totaling €65.8 million ($70.7 million). The funding supports Vico's lead program VO659 in a Phase 1/2a study for spinocerebellar ataxia and Huntington's disease.SerobavcArtica Therapeutics Closes €12M Seed Investment to Develop Covalent Therapeutics for Autoimmune and Inflammatory Disorders – Seroba LifesciencesArtica Therapeutics B.V. has raised €12 million in Seed financing to develop covalent therapeutics for autoimmune and inflammatory disorders. The financing round was co-led by Thuja Capital and Seroba, with additional participation from InnovationQuarter and BGV. Artica aims to enhance its pipeline of small molecule therapies to meet significant unmet medical needs.PR NewswireLeading Femtech Brand INNOVO Attracts Two New InvestorsAtlantic Therapeutics, a Galway-based medtech company, announced it has raised significant new investment from the Borski Fund of the Netherlands and Ireland's Western Development Commission, whose stake represents the largest single investment the WDC has made to date. The financing will support expansion of the company's INNOVO technology—a non-invasive wearable device for treating stress urinary incontinence—into core US and UK markets, with returning investors Seroba Life Sciences, Earlybird, LSP, Andera Partners, and Atlantic Bridge also participating in the round. The company, led by CEO Susan Trent since mid-2020, positions INNOVO as a paradigm shift in the estimated $13 billion urinary incontinence market.HubsIrish Biotech Company Shorla Raises $8.3 Million Series AShorla Pharma, an Irish biotech, raised $8.3 million in a Series A led by Seroba Life Sciences. The company's lead product SH-111 targets T-cell leukemias, with plans to file SH-105 for breast and ovarian cancers by year-end. It also aims to launch SH-110 for glioma in 2022.PR NewswireShorla Pharma Closes $8.3M Series A Funding RoundShorla Pharma, an Irish specialty pharmaceutical company, closed an $8.3 million Series A funding round led by Seroba Life Sciences. The funds will support its oncology drug pipeline and expansion in Ireland and the US. The company, founded by Sharon Cunningham and Orlaith Ryan, focuses on rare and pediatric cancers.PR NewswireSTORM Therapeutics Extends Series A to GBP 30M (USD 38.43M) with New Investor, Seroba Life SciencesSTORM Therapeutics, a Cambridge-based drug discovery company focused on RNA modifying enzymes, has extended its Series A financing by £14 million, bringing the total to £30 million ($38.43 million), with new investor Seroba Life Sciences joining existing investors including Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures, and IP Group. The funding will enable the company to advance its pipeline further in preclinical development and accelerate programs toward clinical stage. The company also appointed Dr Mark Albertella as VP Translational Oncology, who brings over 20 years of oncology drug discovery experience from companies including Medivir AB, AstraZeneca, and OSI Pharmaceuticals.FinSMEsPQ Bypass Receives $60M in Equity FinancingPQ Bypass, a Sunnyvale-based medical device company, received $60M in equity financing led by Deerfield Management, with participation from Seroba Life Sciences and MedTech Venture Partners. The round also converted about $15M in outstanding convertible debt and interest to equity. The company will use the funds to advance clinical development of its DETOUR procedure for treating long blockages in leg arteries.PR NewswireEndotronix Raises $45 Million in Series D Financing for the Treatment of Heart FailureEndotronix closed a $45 million Series D financing round led by LSP, with participation from multiple investors. The funds will support commercialization of the Cordella Heart Failure System and clinical development of the Cordella Sensor, including CE Marking and FDA PMA. The company also plans a landmark PROACTIVE-HF clinical study.